330 related articles for article (PubMed ID: 30632682)
1. Simultaneous bilateral optic neuritis in China: clinical, serological and prognostic characteristics.
Kang H; Liu Z; Li H; Chen T; Ai N; Xu Q; Cao S; Tao Y; Wei S
Acta Ophthalmol; 2019 May; 97(3):e426-e434. PubMed ID: 30632682
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China.
Song H; Zhou H; Yang M; Tan S; Wang J; Xu Q; Liu H; Wei S
Br J Ophthalmol; 2019 Jun; 103(6):831-836. PubMed ID: 30049802
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
[TBL] [Abstract][Full Text] [Related]
4. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis.
Martinez-Hernandez E; Sepulveda M; Rostásy K; Höftberger R; Graus F; Harvey RJ; Saiz A; Dalmau J
JAMA Neurol; 2015 Feb; 72(2):187-93. PubMed ID: 25506781
[TBL] [Abstract][Full Text] [Related]
6. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein.
Ducloyer JB; Michel L; Wiertlewski S; Lebranchu P
Eur J Ophthalmol; 2019 Mar; 29(2):257-261. PubMed ID: 29972029
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis.
Kang H; Chen T; Li H; Xu Q; Cao S; Wei S
J Neurol; 2017 Oct; 264(10):2130-2140. PubMed ID: 28879451
[TBL] [Abstract][Full Text] [Related]
12. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
13. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
[TBL] [Abstract][Full Text] [Related]
14. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
15. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ
Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199
[TBL] [Abstract][Full Text] [Related]
16. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
17. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients.
Zhao Y; Tan S; Chan TCY; Xu Q; Zhao J; Teng D; Fu H; Wei S
Br J Ophthalmol; 2018 Oct; 102(10):1372-1377. PubMed ID: 29363529
[TBL] [Abstract][Full Text] [Related]
19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
Pache F; Zimmermann H; Mikolajczak J; Schumacher S; Lacheta A; Oertel FC; Bellmann-Strobl J; Jarius S; Wildemann B; Reindl M; Waldman A; Soelberg K; Asgari N; Ringelstein M; Aktas O; Gross N; Buttmann M; Ach T; Ruprecht K; Paul F; Brandt AU;
J Neuroinflammation; 2016 Nov; 13(1):282. PubMed ID: 27802824
[TBL] [Abstract][Full Text] [Related]
20. Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.
Jelcic I; Hanson JVM; Lukas S; Weber KP; Landau K; Pless M; Reindl M; Weller M; Martin R; Lutterotti A; Schippling S
J Neuroophthalmol; 2019 Mar; 39(1):3-7. PubMed ID: 30015656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
